July 30 (Reuters) - Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to ...

Eli Lilly (LLY-0.87%) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to ...

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Blue Ash-based drug manufacturer Resilience will expand its operation as client Eli Lilly ramps up production for diabetes ...

Novo is seeking to force Lilly to pull the disputed ads and run corrective ones as the companies compete for dominance in the ...

Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly's KwikPen injectable device in Ohio, aiming ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while ...

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in ...

Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum ...